🇺🇸 FDA
Pipeline program

Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

MG0014

Phase 3 small_molecule active

Quick answer

Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe for Generalized Myasthenia Gravis is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Generalized Myasthenia Gravis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials